P53 family interactions and yeast: Together in anticancer therapy

Sara Gomes, Mariana Leão, Liliana Raimundo, Helena Ramos, Joana Soares, Lucília Saraiva

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understanding of the complex interplay that these proteins establish with murine double minute (MDM)2, MDMX, and mutant p53 could reveal new exciting therapeutic opportunities in cancer treatment. Here, we summarize the most relevant advances in the biology of p53 family protein-protein interactions (PPIs), and the latest pharmacological developments achieved from targeting these interactions. We also highlight the remarkable contributions of yeast-based assays to this research. Collectively, we emphasize promising strategies, based on the inhibition of p53 family PPIs, which have expedited anticancer drug development.

Original languageEnglish
Pages (from-to)616-624
Number of pages9
JournalDrug Discovery Today
Volume21
Issue number4
Early online date15 Feb 2016
DOIs
Publication statusPublished - Apr 2016

Fingerprint Dive into the research topics of 'P53 family interactions and yeast: Together in anticancer therapy'. Together they form a unique fingerprint.

  • Cite this

    Gomes, S., Leão, M., Raimundo, L., Ramos, H., Soares, J., & Saraiva, L. (2016). P53 family interactions and yeast: Together in anticancer therapy. Drug Discovery Today, 21(4), 616-624. https://doi.org/10.1016/j.drudis.2016.02.007